{
    "clinical_study": {
        "@rank": "156278", 
        "arm_group": {
            "arm_group_label": "Candin\u00ae 0.3 mL", 
            "arm_group_type": "Experimental", 
            "description": "Monthly intralesional injections of Candin\u00ae 0.3 ml until lesion resolves or up to 6 injections."
        }, 
        "brief_summary": {
            "textblock": "The primary objective of this study is to determine the safety of Candin\u00ae (Candida albicans\n      Skin Test Antigen) at a 0.3 ml dose level at up to 6 monthly injections for treating common\n      warts (Verruca vulgaris)."
        }, 
        "brief_title": "Candin Safety & Efficacy Study for the Treatment of Warts", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Warts", 
            "Human Papilloma Virus"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Papilloma", 
                "Warts"
            ]
        }, 
        "detailed_description": {
            "textblock": "The primary objective of this study is to determine the safety of Candin\u00ae (Candida albicans\n      Skin Test Antigen) at either 0.3 mL dose levels at up to 6 monthly injections (a maximal,\n      cumulative dose of 1.9 mL, including the delayed-type hypersensitivity (DTH) test) for\n      treating common warts (Verruca vulgaris). A secondary objective is to understand the\n      relative effectiveness of the 0.3 dose level for treating common warts, both those that were\n      injected and those that were not injected as well as other types of warts that were not\n      injected to allow a determination of appropriate dose levels to use in a future dose-ranging\n      efficacy trial."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must have at least 3 and not more than 10 common warts not located on the palms or\n             digits\n\n          -  Positive DTH response to Candin\u00ae required\n\n        Exclusion Criteria:\n\n          -  No previous medical treatment for warts other than OTC\n\n          -  No immunocompromising medical conditions or medicines allowed\n\n          -  No preexisting inflammatory conditions at treatment site allowed"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "39", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01757392", 
            "org_study_id": "Nieslen Protocol CFW-2c"
        }, 
        "intervention": {
            "arm_group_label": "Candin\u00ae 0.3 mL", 
            "description": "0.3 ml injected intralesionally monthly. Number of injections: until wart lesion is resolved or up to 6 injections.", 
            "intervention_name": "Candida albicans Skin Test Antigen", 
            "intervention_type": "Biological", 
            "other_name": "Candin\u00ae"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Treatment", 
            "common wart lesions", 
            "(verruca vulgaris)"
        ], 
        "lastchanged_date": "October 28, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fort Smith", 
                    "country": "United States", 
                    "state": "Arkansas", 
                    "zip": "72916"
                }, 
                "name": "Johnson Dermatology"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Study of the Safety and Effectiveness of Candin for the Treatment of Common Warts", 
        "overall_official": {
            "affiliation": "Johnson Dermatology", 
            "last_name": "Sandy M Johnson, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Symptoms will be evaluated daily for 7 days following each monthly treatment for safety", 
            "measure": "Safety of Candin\u00ae (Candida albicans Skin Test Antigen) at 0.3 dose level at up to 6 monthly injections for treating common warts (Verruca vulgaris)", 
            "safety_issue": "Yes", 
            "time_frame": "Monthly evaluations for up to 5 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01757392"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Presence or absence of wart lesions will be determined monthly", 
            "measure": "Evaluation of the relative efficacy of the 0.3 mL dose levels of Candin\u00ae for up to 5 months", 
            "safety_issue": "No", 
            "time_frame": "Monthly evaluations for up to 5 months"
        }, 
        "source": "Nielsen BioSciences, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nielsen BioSciences, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}